08.05.2025 08:59:53
|
EQS-News: RHÖN-KLINIKUM AG holds steady course in first quarter of 2025 – outlook confirmed
EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Quarter Results/Quarter Results
Corporate News
RHÖN-KLINIKUM AG, one of the largest healthcare providers in Germany, has started into financial year 2025 as expected. From January to March 2025 a total of 240,137 patients were treated in the Group’s hospitals and medical care centres on an outpatient and inpatient basis (Q1 2024: 234,151). Revenue increased by 8.3% to EUR 414.7 million (Q1 2024: EUR 382.8 million). Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to EUR 22.6 million (Q1 2024: EUR 25.2 million). Taking into account the depreciation/amortisation, financing costs and taxes, EBITDA resulted in a consolidated profit of EUR 7.3 million (Q1 2024: EUR 11.1 million). This decrease was primarily driven by the end of funds paid out by the legislator for higher energy expenses and the declining trend in interest rates. “We are operating in a challenging environment and have made a good start into financial year 2025. With our strategic position and close collaboration within the Asklepios Group, Dr. Gunther K. Weiß, member of the Board of Management of RHÖN-KLINIKUM AG, added: “At our five hospital sites of Campus Frankfurt (Oder), Zentralklinik Bad Berka, Campus Bad Neustadt and the university hospitals in Giessen and Marburg, our highly qualified and dedicated employees offer the entire range of modern outpatient and inpatient hospital care, from basic care delivered close to where patients live to highly specialised university medical care. In this way, we ensure that our patients always receive the treatment that is best fit to their needs.”
For the current financial year, we expect revenues of EUR 1.7 billion within a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect This forecast reflects the heightened regulatory interference by the German legislator and the political implementation of the necessary hospital reform. We note that our outlook is subject to considerable uncertainties in connection with the numerous global crises that are resulting among other things in higher prices and supply chain issues, as well as any further regulatory measures impacting our remuneration structure for medical services in 2025.
RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 913,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,700 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
Contact: RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale
08.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | RHÖN-KLINIKUM Aktiengesellschaft |
Salzburger Leite 1 | |
97616 Bad Neustadt a. d. Saale | |
Germany | |
Phone: | +49 (0)9771 - 65-0 |
Fax: | +49 (0)9771 - 97 467 |
E-mail: | rka@rhoen-klinikum-ag.com |
Internet: | www.rhoen-klinikum-ag.com |
ISIN: | DE0007042301 |
WKN: | 704230 |
Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 2132736 |
End of News | EQS News Service |
|
2132736 08.05.2025 CET/CEST
„Silber schlägt Gold?“ – Der geheime Favorit 2025! mit Prof. Dr. Torsten Dennin
💥 Silber 2025: Das unterschätzte Investment?
Im heutigen BX Swiss TV Experteninterview spricht Prof. Dr. Torsten Dennin (CIO der Asset Management Switzerland AG) darüber, warum Silber aktuell das vielleicht spannendste Rohstoff-Investment überhaupt ist.
Gemeinsam mit Olivia Hähnel (BX Swiss) beantwortet er folgende Fragen:
👉 Ist Silber der neue Geheimfavorit gegenüber Gold?
👉 Welche Rolle spielt der Boom bei Solar und Hightech für die Preisentwicklung?
👉 Und wie kann man als Anleger konkret profitieren – mit welchen Chancen und Risiken?
🔍 Das erwartet euch im Interview:
◽ Aktuelle Marktsituation und Hintergründe zum Silberpreis
◽ Gold vs. Silber: Unterschiede & Investmentpotenzial
◽ Industrielle Treiber: Solar, Energiewende, Zukunftstechnologien
◽ Angebot, Nachfrage & Lagerbestände: Warum der Markt im Defizit ist
◽ Investieren in Silber: physisch, ETFs, Zertifikate, Minenaktien
◽ Chancen & Risiken von Explorationsunternehmen vs. Produzenten
◽ Strategien für sicherheitsorientierte Anleger
◽ Prognose: 45–50 USD – oder mehr?
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Trotz iranischem Gegenschlag: US-Börsen fahren Gewinne ein -- SMI und DAX schliessen schwächer -- Asiens Börsen letztlich mehrheitlich etwas höherDer heimische sowie der deutsche Aktienmarkt konnten am Montag ihre anfänglichen Verluste teilweise abschütteln. Die US-Börsen ziehen am Montag an. In Asien gingen die Börsen mehrheitlich höher aus dem Handel.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |